SVCM
COGT icon

Saturn V Capital Management’s Cogent Biosciences COGT Stock Holding History

Saturn V Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-626,635
Closed -$24.1M – 24
2026
Q1 		$24.1M Sell
626,635
-590,429
-49% -$21.8M 4.37% 11
2025
Q4 		$43.2M Sell
1,217,064
-807,977
-40% -$22.7M 7.93% 3
2025
Q3 		$29.1M Sell
2,025,041
-272,483
-12% -$3.23M 6.38% 5
2025
Q2 		$16.5M Buy
2,297,524
+817,504
+55% +$4.53M 6.69% 5
2025
Q1 		$8.87M Sell
1,480,020
-18,405
-1% -$144K 4.47% 9
2024
Q4 		$11.7M Sell
1,498,425
-214,474
-13% -$2.14M 4.58% 12
2024
Q3 		$18.5M Buy
1,712,899
+38,980
+2% +$380K 6.61% 5
2024
Q2 		$14.1M Buy
1,673,919
+78,898
+5% +$598K 5.33% 8
2024
Q1 		$10.7M Buy
1,595,021
+838,340
+111% +$5.18M 4.3% 10
2023
Q4 		$4.45M Sell
756,681
-1,018,734
-57% -$7.81M 1.7% 17
2023
Q3 		$17.3M Buy
1,775,415
+632,047
+55% +$7.5M 7.25% 3
2023
Q2 		$13.5M Buy
+1,143,368
New +$13.1M 7.51% 3

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Saturn V Capital Management's COGT Position: Q2 2026 in Review

Saturn V Capital Management sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 626,635 shares — an estimated $24.1M sold.

Saturn V Capital Management first reported a position in COGT in Q2 2023 and held it in 12 quarters. The position peaked at $43.2M in Q4 2025. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Saturn V Capital Management reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
  • Saturn V Capital Management sold 626,635 Cogent Biosciences shares in Q2 2026, an estimated $24.1M.
  • Saturn V Capital Management first reported a position in Cogent Biosciences in Q2 2023 and held it in 12 quarters.
  • Saturn V Capital Management's Cogent Biosciences position peaked at $43.2M in Q4 2025.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.